Table 2. Engraftment in sensitized... | American Society of Hematology

Table 2.

Engraftment in sensitized recipients reconstituted between 12 and 13 weeks with untreated donor BMCs

Donor no.	mAb	TBI, cGy	BMCs	MFI,†11-12 wk	Engraftment, % 1 mo	Donor, % 1 mo
8	Anti-CD8	950	80 × 10⁶	80.2 ± 36.2	37.5	99.7 ± 0.5
4	Anti-CD154	950	80 × 10⁶	101.7 ± 68.7	25	100
7	Anti-CD8/CD154	950	80 × 10⁶	69.5 ± 23.4	85.7	94.8 ± 5.4
8	Anti-CD8/CD154	850	80 × 10⁶	62.6 ± 47.3	25	95.0, 97.9
4	Anti-CD8/CD154	950	40 × 10⁶	56.8 ± 34.8	0	NA
9	None	950	3 × 40 × 10⁶^*	93.8 ± 57.2	44.4	96.3 ± 3.4

Donor no.	mAb	TBI, cGy	BMCs	MFI,†11-12 wk	Engraftment, % 1 mo	Donor, % 1 mo
8	Anti-CD8	950	80 × 10⁶	80.2 ± 36.2	37.5	99.7 ± 0.5
4	Anti-CD154	950	80 × 10⁶	101.7 ± 68.7	25	100
7	Anti-CD8/CD154	950	80 × 10⁶	69.5 ± 23.4	85.7	94.8 ± 5.4
8	Anti-CD8/CD154	850	80 × 10⁶	62.6 ± 47.3	25	95.0, 97.9
4	Anti-CD8/CD154	950	40 × 10⁶	56.8 ± 34.8	0	NA
9	None	950	3 × 40 × 10⁶^*	93.8 ± 57.2	44.4	96.3 ± 3.4

NA indicates not applicable

Three doses of 40 × 10⁶ BMCs on days 0, 2, and 4 relative to TBI

MFI is presented as mean ± SD